Collegium Pharmaceutical, Inc.

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
36.42 ^USD	+1.62%		+4.54%	+18.32%

Apr. 11	Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	MT
Feb. 26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

February 22, 2024 at 04:09 pm EST

Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the full year 2024. For the year, the company expects Product Revenues to be between $580.0 million to $595.0 million.

Latest news about Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	Apr. 11	MT
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	Feb. 26	MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	Feb. 26	MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase	Feb. 23	MT
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26	Feb. 22	MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
North American Morning Briefing : Bond Yields Rise -2-	Jan. 05	DJ
Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	Jan. 04	MT
Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	Jan. 04	MT
North American Morning Briefing: S&P 500 Futures Nudge Higher After Weak Start to the Year	Jan. 04	DJ
Health Care Dips on Defensive Rotation - Health Care Roundup	Jan. 03	DJ
Collegium Pharmaceutical Expects Net Product Revenue of up to $595 Million in 2024	Jan. 03	MT
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 4, 2023.	Jan. 03	CI
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $150 million worth of its shares.	Jan. 03	CI
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2024	Jan. 03	CI
Collegium Pharmaceutical, Inc. authorizes a Buyback Plan.	Dec. 31	CI
Collegium Pharmaceutical, Inc.'s Equity Buyback announced on January 4, 2023, has expired with 3,088,069 shares, representing 9.09% for $75 million.	Dec. 30	CI
Collegium Pharmaceutical Insider Sold Shares Worth $2,075,086, According to a Recent SEC Filing	Dec. 21	MT
Transcript : Collegium Pharmaceutical, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q3 EPS $1.34, vs. Street Est of $1.24	Nov. 07	MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q3 Revenue $136.7M, vs. Street Est of $139.5M	Nov. 07	MT
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI

Chart Collegium Pharmaceutical, Inc.

Duration

Period

More charts

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Collegium Pharmaceutical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

36.42 USD

Average target price

40 USD

Spread / Average Target

+9.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
COLLEGIUM PHARMACEUTICAL, INC.	+18.32%	1.19B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals